Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy

Aberrant fibroblast growth factor receptor (FGFR) activation/expression is a common feature in lung cancer (LC). In this study, we evaluated the antitumor activity of and the mechanisms underlying acquired resistance to two potent selective FGFR inhibitors, AZD4547 and BAY116387, in LC cell lines. T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncogenesis
Autores principales: Kim, S-M, Kim, H, Yun, M R, Kang, H N, Pyo, K-H, Park, H J, Lee, J M, Choi, H M, Ellinghaus, P, Ocker, M, Paik, S, Kim, H R, Cho, B C
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5399172/
https://ncbi.nlm.nih.gov/pubmed/27429073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2016.48
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares